• AI
  • Molecular Imaging
  • CT
  • X-Ray
  • Ultrasound
  • MRI
  • Facility Management
  • Mammography

AI Software for Brain MRI Gets Expanded FDA Clearance for Multiple Sclerosis Assessment

News
Article

Through AI technology, Neurophet AQUA now provides multiple sclerosis (MS) analysis with a combination of lesion quantification and enhanced segmentation of T2-FLAIR MRI.

The Food and Drug Administration (FDA) has granted expanded 510(k) clearance for multiple sclerosis (MS) assessment with the magnetic resonance imaging (MRI)-based artificial intelligence (AI) software Neurophet AQUA.

Previously FDA-cleared for assessment of brain atrophy on MRI, Neurophet AQUA offers advanced analysis of MS and white matter hyperintensities based off of T2-weighted fluid-attention inversion recovery (FLAIR) MRI, according to Neurophet, the developer of Neurophet AQUA.

AI Software for Brain MRI Gets Expanded FDA Clearance for Multiple Sclerosis Assessment

Based off brain MRI images, the AI-enabled software Neurophet AQUA reportedly offers quantification of lesions and structural changes associated with multiple sclerosis (MS) and volumetric brain region assessment without the need for 3D T1 images. The Neurophet AQUA software recently garnered expanded FDA 510(k) clearance for MS assessment. (Image courtesy of Adobe Stock.)

The company said key features of the AI-powered software’s MS analysis include:

• precise assessment of lesion count, volume and progression through enhanced quantification of lesions and structural changes;

• volumetric brain region assessment without the need for 3D T1 images; and

• bolstered segmentation of T2-weighted FLAIR images at 2D and 3D on 1.5T and 3T MRI platforms.

"MS is a neurological disorder that heavily relies on MRI for both diagnosis and disease monitoring, and the McDonald criteria, the diagnostic criteria for MS, specifically includes MRI confirmation of lesions disseminated in space and time," said Jake Junkil Been, the co-CEO of Neurophet. "Neurophet AQUA's advanced MS analysis technology significantly enhances efficiency and convenience for healthcare professionals, making it an indispensable tool in both diagnostic and prognostic stages."

Recent Videos
What New Brain MRI Research Reveals About Cannabis Use and Working Memory Tasks
Radiology Study Finds Increasing Rates of Non-Physician Practitioner Image Interpretation in Office Settings
Addressing the Early Impact of National Breast Density Notification for Mammography Reports
Where the USPSTF Breast Cancer Screening Recommendations Fall Short: An Interview with Stacy Smith-Foley, MD
A Closer Look at MRI-Guided Transurethral Ultrasound Ablation for Intermediate Risk Prostate Cancer
Improving the Quality of Breast MRI Acquisition and Processing
Can Diffusion Microstructural Imaging Provide Insights into Long Covid Beyond Conventional MRI?
Emerging MRI and PET Research Reveals Link Between Visceral Abdominal Fat and Early Signs of Alzheimer’s Disease
Nina Kottler, MD, MS
Practical Insights on CT and MRI Neuroimaging and Reporting for Stroke Patients
Related Content
Multimodal AI with CCTA and MRI Data Shows Promise in Predicting MACE in Patients with Obstructive CAD

Multimodal AI with CCTA and MRI Data Shows Promise in Predicting MACE in Patients with Obstructive CAD

Jeff Hall
January 29th 2025
Article

For patients with newly diagnosed obstructive coronary artery disease (CAD), a multimodal machine learning model offered an 86 percent AUC for predicting MACE, which was 10 percent higher than CCTA alone and over 35 percent higher than the Framingham Risk Score.

MindMoments: Consensus MRI Guidelines for Multiple Sclerosis

MindMoments: Consensus MRI Guidelines for Multiple Sclerosis

Matt Hoffman
July 3rd 2021
Podcast

An interview with two experts to discuss newly released guidance for using standardized MRI protocols for patients with this condition.

MRI Study Reveals Early Differences in Mild Cognitive Impairment Preceding Alzheimer’s Disease and Parkinson’s Disease

MRI Study Reveals Early Differences in Mild Cognitive Impairment Preceding Alzheimer’s Disease and Parkinson’s Disease

Jeff Hall
January 21st 2025
Article

For patients with mild cognitive impairment (MCI), early changes with respect to decreased intra-network connectivity involving the default mode network or salience network may aid in differentiating between the development of Alzheimer’s disease and Parkinson’s disease, according to new MRI research.

The Reading Room: Potential fMRI Alternative -- fPACT

The Reading Room: Potential fMRI Alternative -- fPACT

Whitney J. Palmer
June 23rd 2021
Podcast

Drs. Charles Liu and Jonathan Russin discuss the benefits and potential of fPACT, the alternative to functional MRI.

FDA Clears Brain MRI-Based Software for Assessing Cortical Disarray Measurement

FDA Clears Brain MRI-Based Software for Assessing Cortical Disarray Measurement

Jeff Hall
January 16th 2025
Article

The CDM Insights software, which can be utilized with scans from 1.5T and 3T MRI, reportedly provides new measurements of cortical thickness and brain microstructure.

Can Generative AI Facilitate Simulated Contrast Enhancement for Prostate MRI?

Can Generative AI Facilitate Simulated Contrast Enhancement for Prostate MRI?

Jeff Hall
January 14th 2025
Article

Deep learning synthesis of contrast-enhanced MRI from non-contrast prostate MRI sequences provided an average multiscale structural similarity index of 70 percent with actual contrast-enhanced prostate MRI in external validation testing from newly published research.

© 2025 MJH Life Sciences

All rights reserved.